

SCHEDULE OF INVESTMENTS

March 31, 2021

BIOTECHNOLOGY FUND

	SHARES	VALUE		SHARES	VALUE
COMMON STOCKS[†] - 99.5%					
BIOTECHNOLOGY - 73.4%					
Amgen, Inc.	41,014	\$ 10,204,693			
Gilead Sciences, Inc.	118,157	7,636,487			
Vertex Pharmaceuticals, Inc.*	29,460	6,330,659			
Illumina, Inc.*	15,933	6,119,228			
Regeneron Pharmaceuticals, Inc.*	12,686	6,002,254			
Moderna, Inc.*	44,894	5,878,869			
Biogen, Inc.*	20,330	5,687,318			
Corteva, Inc.	106,161	4,949,226			
Alexion Pharmaceuticals, Inc.*	32,150	4,916,057			
Seagen, Inc.*	29,839	4,143,444			
Exact Sciences Corp.*	30,664	4,040,902			
Incyte Corp.*	44,724	3,634,719			
Bio-Rad Laboratories, Inc. — Class A*	6,140	3,506,984			
Alynlyam Pharmaceuticals, Inc.*	24,388	3,443,342			
Guardant Health, Inc.*	22,476	3,430,961			
CRISPR Therapeutics AG*	25,540	3,112,049			
BioMarin Pharmaceutical, Inc.*	40,899	3,088,283			
BioNTech SE ADR* ¹	26,220	2,862,962			
Novavax, Inc.*	15,550	2,819,370			
BeiGene Ltd. ADR*	7,020	2,443,522			
Mirati Therapeutics, Inc.*	14,233	2,438,113			
Acceleron Pharma, Inc.*	17,962	2,435,827			
Fate Therapeutics, Inc.*	27,870	2,297,882			
United Therapeutics Corp.*	13,638	2,281,228			
Ultragenyx Pharmaceutical, Inc.*	19,929	2,269,116			
TG Therapeutics, Inc.*	46,620	2,247,084			
Exelixis, Inc.*	98,564	2,226,561			
Arrowhead Pharmaceuticals, Inc.*	32,997	2,188,031			
Twist Bioscience Corp.*	16,700	2,068,462			
Blueprint Medicines Corp.*	20,430	1,986,409			
Halozyne Therapeutics, Inc.*	47,420	1,976,940			
Ionis Pharmaceuticals, Inc.*	43,579	1,959,312			
Emergent BioSolutions, Inc.*	20,730	1,926,024			
Iovance Biotherapeutics, Inc.*	57,964	1,835,140			
Sage Therapeutics, Inc.*	23,526	1,760,921			
Biohaven Pharmaceutical Holding Company Ltd.*	25,170	1,720,370			
Arena Pharmaceuticals, Inc.*	24,270	1,684,095			
ACADIA Pharmaceuticals, Inc.*	64,903	1,674,497			
ChemoCentryx, Inc.*	30,430	1,559,233			
PTC Therapeutics, Inc.*	30,028	1,421,826			
Editas Medicine, Inc.*	33,300	1,398,600			
Amicus Therapeutics, Inc.*	136,080	1,344,470			
Global Blood Therapeutics, Inc.*	32,095	1,307,871			
Bluebird Bio, Inc.*	39,725	1,197,709			
Inovio Pharmaceuticals, Inc.* ¹	122,560	1,137,357			
Total Biotechnology		<u>140,594,407</u>			
PHARMACEUTICALS - 17.2%					
AbbVie, Inc.	110,062	11,910,910			
Horizon Therapeutics plc*	42,545	3,915,842			
Viartis, Inc.*	242,687	3,390,337			
PRA Health Sciences, Inc.*	17,635	2,703,975			
Neurocrine Biosciences, Inc.*	27,296	2,654,536			
Jazz Pharmaceuticals plc*	16,047	\$ 2,637,645			
Intellia Therapeutics, Inc.*	27,870	2,236,707			
Sarepta Therapeutics, Inc.*	26,089	1,944,413			
Pacira BioSciences, Inc.*	21,190	1,485,207			
Total Pharmaceuticals		<u>32,879,572</u>			
HEALTHCARE-PRODUCTS - 5.4%					
Bio-Techne Corp.	8,588	3,280,015			
Novocure Ltd.*	19,933	2,634,744			
Natera, Inc.*	24,960	2,534,438			
Adaptive Biotechnologies Corp.*	48,760	1,963,078			
Total Healthcare-Products		<u>10,412,275</u>			
HEALTHCARE-SERVICES - 3.5%					
Syneos Health, Inc.*	31,060	2,355,901			
Invitae Corp.* ¹	59,390	2,269,292			
Medpace Holdings, Inc.*	12,570	2,062,108			
Total Healthcare-Services		<u>6,687,301</u>			
Total Common Stocks					
(Cost \$103,366,793)					<u>190,573,555</u>
RIGHTS^{†††} - 0.0%					
BIOTECHNOLOGY - 0.0%					
Clinical Data, Inc.*	24,000	—			
Total Rights		—			—
			FACE		
			AMOUNT		
REPURCHASE AGREEMENTS^{†††2} - 0.2%					
J.P. Morgan Securities LLC issued 03/31/21 at 0.01% due 04/01/21			\$ 203,318		203,318
Barclays Capital, Inc. issued 03/31/21 at 0.01% due 04/01/21			92,438		92,438
BofA Securities, Inc. issued 03/31/21 at 0.01% due 04/01/21			84,365		84,365
Total Repurchase Agreements					<u>380,121</u>
(Cost \$380,121)					
			SHARES		
SECURITIES LENDING COLLATERAL^{†3} - 2.3%					
Money Market Fund					
First American Government Obligations Fund — Class Z, 0.03% ⁴	4,514,930				4,514,930
Total Securities Lending Collateral					<u>4,514,930</u>
(Cost \$4,514,930)					
Total Investments - 102.0%					
(Cost \$108,261,844)					<u>\$ 195,468,606</u>
Other Assets & Liabilities, net - (2.0%)					
					<u>(3,860,430)</u>
Total Net Assets - 100.0%					
					<u>\$ 191,608,176</u>

BIOTECHNOLOGY FUND

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

¹ All or a portion of this security is on loan at March 31, 2021.

² Repurchase Agreements.

³ Securities lending collateral.

⁴ Rate indicated is the 7-day yield as of March 31, 2021.

ADR — American Depositary Receipt

plc — Public Limited Company